China SXT Pharmaceuticals

SXTC

Q4 FY2026 Earnings

Financial report interval: 2025.12.31 - 2026.03.31

Overview: China SXT Pharmaceuticals(SXTC) the Revenue is 255.74 K (-43.88%);the EBIT is -392.01 K (+61.61%).

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B43.88%
----
----
EBIT
-0.00B61.61%
----
----

Revenue

ActualEstimateUnit: USD
Quarterly

EBIT

ActualEstimateUnit: USD
Quarterly

Net income

ActualEstimateUnit: USD
Quarterly

EPS

ActualEstimateUnit: USD
Quarterly